![](https://endpts.com/wp-content/uploads/2023/12/Spiros-Liras-Paul-Da-Silva-Jardine-Deep-Apple-tile.jpg)
Deep Apple Therapeutics CEO Spiros Liras (L) and interim CSO Paul Da Silva Jardine
Former execs from Pfizer obesity drug program have started a new biotech with $52M from VC fund ATP
Two former chemistry VPs who worked at Pfizer’s cardiovascular and metabolic research group have come together to build a new biotech as the obesity drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.